MX2022004157A - Metodo de tratamiento de pacientes con sindrome hepatorrenal tipo 1 y presion arterial media baja. - Google Patents

Metodo de tratamiento de pacientes con sindrome hepatorrenal tipo 1 y presion arterial media baja.

Info

Publication number
MX2022004157A
MX2022004157A MX2022004157A MX2022004157A MX2022004157A MX 2022004157 A MX2022004157 A MX 2022004157A MX 2022004157 A MX2022004157 A MX 2022004157A MX 2022004157 A MX2022004157 A MX 2022004157A MX 2022004157 A MX2022004157 A MX 2022004157A
Authority
MX
Mexico
Prior art keywords
patient
arterial pressure
mean arterial
hrs
map
Prior art date
Application number
MX2022004157A
Other languages
English (en)
Spanish (es)
Inventor
Khurram Jamil
Stephen Chris Pappas
Peter Teuber
Original Assignee
Mallinckrodt Hospital Products IP Unlimited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Hospital Products IP Unlimited Company filed Critical Mallinckrodt Hospital Products IP Unlimited Company
Publication of MX2022004157A publication Critical patent/MX2022004157A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MX2022004157A 2019-10-30 2020-10-29 Metodo de tratamiento de pacientes con sindrome hepatorrenal tipo 1 y presion arterial media baja. MX2022004157A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962928152P 2019-10-30 2019-10-30
PCT/IB2020/060185 WO2021084483A1 (en) 2019-10-30 2020-10-29 Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure

Publications (1)

Publication Number Publication Date
MX2022004157A true MX2022004157A (es) 2022-07-19

Family

ID=73060034

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004157A MX2022004157A (es) 2019-10-30 2020-10-29 Metodo de tratamiento de pacientes con sindrome hepatorrenal tipo 1 y presion arterial media baja.

Country Status (10)

Country Link
US (1) US20210128676A1 (https=)
EP (1) EP4051310A1 (https=)
JP (1) JP2023500654A (https=)
KR (1) KR20220092868A (https=)
CN (1) CN114980914A (https=)
AU (1) AU2020373408A1 (https=)
BR (1) BR112022006329A2 (https=)
CA (1) CA3159575A1 (https=)
MX (1) MX2022004157A (https=)
WO (1) WO2021084483A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240019089A (ko) * 2021-06-07 2024-02-14 말린크로트 파마슈티칼스 아일랜드 리미티드 간신장 증후군 1형 환자의 치료 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015203036A1 (en) * 2010-07-14 2015-07-02 Cumberland Emerging Technologies, Inc Methods of Treating Hepatorenal Syndrom and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
US10335452B2 (en) * 2014-10-24 2019-07-02 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1

Also Published As

Publication number Publication date
CA3159575A1 (en) 2021-05-06
EP4051310A1 (en) 2022-09-07
US20210128676A1 (en) 2021-05-06
JP2023500654A (ja) 2023-01-10
CN114980914A (zh) 2022-08-30
KR20220092868A (ko) 2022-07-04
AU2020373408A1 (en) 2022-04-21
BR112022006329A2 (pt) 2022-08-16
WO2021084483A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
EP4233861A3 (en) Compositions for treatment of essential tremor
RU2008109238A (ru) Способы лечения заболеваний антагонистами vegf
JP2017501154A5 (https=)
FI3978074T3 (fi) Terlipressiini tyypin 1 hepatorenaalisen syndrooman hoitamiseksi
MX2022004157A (es) Metodo de tratamiento de pacientes con sindrome hepatorrenal tipo 1 y presion arterial media baja.
Sahu et al. Comparison of bolus phenylephrine, ephedrine and mephentermine for maintenance of arterial pressure during spinal anaesthesia in caesarean section–a clinical study
EA202090558A1 (ru) Схемы лечения
Lee et al. The effect of dexmedetomidine on propofol injection pain
US7470666B2 (en) Use of Ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndrome
MX2025009838A (es) Métodos de tratamiento de la hipertensión con síndrome metabólico mediante manp
Tokumine et al. Tissue necrosis caused by extravasated propofol.
ATE85521T1 (de) Verwendung von acetyl-l-carnitin zur herstellung eines arzneimittels zur therapeutischen behandlung von schockzustaenden.
MX2024005374A (es) Metodos para tratar la enfermedad de celulas falciformes con voxelotor.
Zhang et al. Intraoperative tumor lysis-induced fatal hyperkalemia
MX2024004355A (es) Tratamiento de la enfermedad renal.
DE202012100195U1 (de) Neue Verwendung einer pharmazeutischen Zusammensetzung, enthaltend Ancrod
MA62049B1 (fr) Composé de dégradation dans un médicament
SU1123662A1 (ru) Способ профилактики послеоперационного тромбоза глубоких вен нижних конечностей
JP2023500654A5 (https=)
Swingle et al. A study of gelatin and saline as plasma substitutes
Matsumoto et al. Early use of brachial-basilic arteriovenous fistula
Coyas The anticoagulant treatment of certain forms of sudden deafness
Jeong et al. Systemic capillary leak syndrome under general anesthesia: a case report
Ki et al. Tension hydrothorax induced by malposition of central venous catheter-A case report
UA117797C2 (uk) Спосіб лікування трофічних виразок при хронічній венозній недостатності